Skip to main
COAG

COAG Stock Forecast & Price Target

COAG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hemab Therapeutics Hldgs is a promising clinical-stage biotechnology company that is developing potentially life-changing therapies for blood coagulation disorders. Its flagship candidate, sutacimig, has shown promising results in clinical trials for the treatment of Glanzmann thrombasthenia and Factor VII deficiency, and the company's pipeline of other assets, such as HMB-002 for Von Willebrand Disease and HMB-003 for heavy menstrual bleeding, offer additional potential upside. Additionally, a recent successful financing round and promising data from a competitor's clinical trial highlight the potential demand for Hemab's therapies and increase confidence in the company's future success.

Bears say

Hemab Therapeutics Hldgs is a clinical-stage biotechnology company with promising pipeline drugs aimed at treating bleeding disorders. However, despite strong data for its lead candidate sutacimig, the recent clotting events in higher exposure cohorts may indicate potential safety concerns for the drug. Additionally, competitor programs may offer a broader target patient population for their VWD treatments, raising questions about Hemab's long-term market potential.

COAG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hemab Therapeutics Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hemab Therapeutics Holdings Inc (COAG) Forecast

Analysts have given COAG a Strong Buy based on their latest research and market trends.

According to 5 analysts, COAG has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hemab Therapeutics Holdings Inc (COAG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.